Aspen Investor Presentation — June 2021

Document content

Year End Results Presentation

For the 12 months ended 30 June 2021DISCLAIMER

We may make statements that are not historical facts and relate to analyses and other information based on forecasts of futur e results and estimates of amounts

not yet determinable. These are forward looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Words such as “prospects”,

“believe”, “anticipate”, “expect”, “intend”, “seek”, “will”, “plan”, “indicate”, “could”, “may”, “endeavour” and “project” an d similar expressions are intended to

identify such forward looking statements, but are not the exclusive means of identifying such statements. By their very natur e, forward -looking statements involve

inherent risks and uncertainties, both general and specific, and there are risks that predictions, forecasts, projections and other forward- looking statements will

not be achieved. If one or more of these risks materialise, or should underlying assumptions prove incorrect, actual results may be very different from those

anticipated. The factors that could cause our actual results to differ materially from the plans, objectives, expectations, e stimates and intentions expressed in such

forward -looking statements are discussed in each year’s annual report. ​

Forward looking statements apply only as of the date on which they are made, and we do not undertake other than in terms of t he Listings Requirements of the

JSE Limited, any obligation to update or revise any of them, whether as a result of new information, future events or otherwi se.Any profit forecasts published in

this report are unaudited and have not been reviewed or reported on by Aspen's external auditors. ​

2CAUTIONARY REGARDING FORWARD -LOOKING STATEMENTSDISCLOSURE NOTE

Discontinued European Business

The discontinued European business comprises the European Thrombosis Assets divested to Mylan until the date of disposal, bei ng 27 November 2020, the costs

relating to its disposal, related Thrombosis product discontinuations and other product divestments. The results of the disco ntinued European Business and the

residual costs relating to prior period disposals have been classified as discontinued operations in terms of IFRS 5 and have been reported separately in the

discontinued operations statement of comprehensive income including a restatement of comparative periods.

The prior year finance costs previously shown as attributable to discontinued operations have been reclassified to be include d in continuing operations. The

resultant restatement of the comparative numbers for continuing and discontinued operations is not material with the value of finance costs being reclassified